We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+6.38%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.96B
AUM Growth
+$853M
Cap. Flow
+$1.08B
Cap. Flow %
13.6%
Top 10 Hldgs %
33.59%
Holding
163
New
28
Increased
23
Reduced
24
Closed
20

Top Buys

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$440M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$270M
3
AFIB
Acutus Medical Inc
AFIB
+$166M
4
ACET icon
Adicet Bio
ACET
+$95.1M
5
TBPH icon
Theravance Biopharma
TBPH
+$68.6M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$119M
2
CI icon
Cigna
CI
+$82.5M
3
NTRA icon
Natera
NTRA
+$64.2M
4
ALEC icon
Alector
ALEC
+$52.6M
5
GKOS icon
Glaukos
GKOS
+$46.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 0.63%
3 Technology 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
51
Stryker
SYK
$134B
$49M 0.62%
+235,000
New +$45.7M
TMO icon
52
Thermo Fisher Scientific
TMO
$215B
$48.7M 0.61%
110,300
– –
ATNX
53
DELISTED
Athenex, Inc. Common Stock
ATNX
$48.1M 0.61%
198,898
-1,569
-0.8% -$377K
ADVM
54
DELISTED
Adverum Biotechnologies
ADVM
$47.2M 0.59%
458,434
+129,360
+39% +$19.4M
CHNG
55
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$44.9M 0.56%
+3,093,700
New +$39.3M
CRNX icon
56
Crinetics Pharmaceuticals
CRNX
$8.88B
$43.1M 0.54%
2,753,567
– –
KALA icon
57
KALA BIO
KALA
$12M
$41M 0.52%
2,188
+25
+1% +$575K
ABBV icon
58
AbbVie
ABBV
$471B
$40.6M 0.51%
464,000
– –
FUSN
59
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$38.8M 0.49%
3,224,770
– –
SCPH
60
DELISTED
scPharmaceuticals
SCPH
$35.7M 0.45%
4,797,148
– –
QURE icon
61
uniQure
QURE
$2.73B
$35.7M 0.45%
969,079
– –
VRNA
62
DELISTED
Verona Pharma
VRNA
$35.5M 0.45%
5,694,841
+4,444,445
+355% +$30.7M
PRTA icon
63
Prothena Corp
PRTA
$443M
$35.4M 0.45%
3,544,475
– –
ACHC icon
64
Acadia Healthcare
ACHC
$2.56B
$32.9M 0.41%
1,114,466
-265,694
-19% -$7.71M
SIBN icon
65
SI-BONE Inc
SIBN
$804M
$32.5M 0.41%
1,368,500
-12,800
-0.9% -$254K
ALPN
66
DELISTED
Alpine Immune Sciences Inc
ALPN
$32.3M 0.41%
3,670,955
– –
APLT
67
DELISTED
Applied Therapeutics
APLT
$32.1M 0.4%
1,546,687
+329,009
+27% +$8.55M
PCVX icon
68
Vaxcyte
PCVX
$7.71B
$31.6M 0.4%
640,760
-209,240
-25% -$8.33M
HARP
69
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$31.2M 0.39%
183,570
– –
ALEC icon
70
Alector
ALEC
$171M
$28.7M 0.36%
2,725,313
-3,250,009
-54% -$52.6M
NBP
71
NovaBridge Biosciences American Depositary Shares
NBP
$192M
$28.5M 0.36%
+606,070
New +$20M
SYRE icon
72
Spyre Therapeutics
SYRE
$8.3B
$28.5M 0.36%
160,621
– –
XENE icon
73
Xenon Pharmaceuticals
XENE
$6.21B
$27.7M 0.35%
2,497,917
– –
PFE icon
74
CALL
Pfizer
PFE
$144B
$27.5M 0.35%
+790,500
New +$27.7M
SVA
75
DELISTED
Sinovac Biotech, Ltd
SVA
$27.3M 0.34%
2,839,500
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2020 Portfolio in Review

As of Q3 2020, OrbiMed held 163 positions worth $7.96B, up 12% from $7.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed deployed $1.08B of net new capital in Q3 2020, opening 28 new positions and adding to 23 existing holdings. Its largest new stake was Prelude Therapeutics: 15,594,877 shares worth $470M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $119M trimmed.

  • OrbiMed's largest Q3 2020 buy was Prelude Therapeutics: 15,594,877 shares worth $470M.
  • OrbiMed added most to Adicet Bio in Q3 2020, an estimated $95.1M increase.
  • OrbiMed's biggest Q3 2020 reduction was Ascendis Pharma A/S, cutting an estimated $119M.
  • OrbiMed fully exited Cigna in Q3 2020, selling an estimated $82.5M.
  • OrbiMed's ten largest holdings make up 34% of its $7.96B portfolio in Q3 2020.
  • OrbiMed opened 28 new positions and closed 20 in Q3 2020.
  • OrbiMed's portfolio value rose 12% quarter-over-quarter to $7.96B.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.